Anogenital warts (AGWs) are the earliest clinical manifestation of infection with human
papillomavirus (HPV). Two vaccines can prevent nearly all cases of AGW. 1 In 2013 …

Objectives. To detect decreases in anogenital warts (AGW) among sex and age groups
likely to be affected by human papillomavirus vaccination. Methods. We estimated annual …

Introduction Evidence of human papillomavirus (HPV) vaccine impact on anogenital warts
(AGWs) by race or urbanicity in the US is lacking. We evaluated HPV vaccine impact in …

Background Studies in countries with high human papillomavirus (HPV) vaccination
coverage have demonstrated marked reductions in anogenital wart (AGW) incidence. Our …

Background Approximately 90% of genital warts are caused by human papillomavirus (HPV)
types 6 and 11. In the United States, HPV vaccination has been recommended for girls and …

Objectives. We estimated anogenital wart prevalence from 2003 to 2010 by gender and age
group in a large US cohort with private insurance to detect potential decreases among …

Chronic infection with human papillomavirus (HPV) causes more than 300,000 cases of
genital warts and nearly 26,000 new cancers in the United States each year, incurring costs …

Introduction Quadrivalent human papillomavirus (HPV) vaccine was first licensed for use in
the United States (US) for females in June 2006. Vaccination uptake has increased over …

Background Assessing the impact and effectiveness of HPV vaccines on anogenital warts in
the United States can provide early indication of the success of vaccination programs as well …

Background In 2008, British Columbia (BC) implemented a school-based quadrivalent
human papillomavirus (HPV-4) immunization program for girls born in 1994 or later. In 2015 …